Leerink Partnrs Analysts Boost Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Leerink Partnrs lifted their FY2025 earnings estimates for Neurocrine Biosciences in a research report issued to clients and investors on Thursday, September 7th. Leerink Partnrs analyst M. Goodman now expects that the company will earn $5.80 per share for the year, up from their previous forecast of $5.55. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $2.17 per share.

NBIX has been the subject of a number of other reports. BMO Capital Markets upped their target price on Neurocrine Biosciences from $96.00 to $100.00 and gave the stock a “market perform” rating in a research report on Wednesday, August 2nd. Morgan Stanley reissued an “overweight” rating and set a $130.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, August 2nd. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 5th. HC Wainwright upped their price objective on shares of Neurocrine Biosciences from $140.00 to $146.00 and gave the stock a “buy” rating in a report on Monday, August 21st. Finally, Canaccord Genuity Group upped their target price on Neurocrine Biosciences from $130.00 to $132.00 and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $126.96.

Neurocrine Biosciences Trading Up 0.7 %

Shares of NASDAQ NBIX opened at $109.27 on Monday. Neurocrine Biosciences has a 12-month low of $89.04 and a 12-month high of $129.29. The stock has a 50 day simple moving average of $102.65 and a 200-day simple moving average of $99.51. The company has a market cap of $10.67 billion, a PE ratio of 63.16, a P/E/G ratio of 1.09 and a beta of 0.46.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.18. The company had revenue of $452.70 million for the quarter, compared to analysts’ expectations of $448.29 million. Neurocrine Biosciences had a return on equity of 10.39% and a net margin of 10.54%.

Institutional Investors Weigh In On Neurocrine Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its position in shares of Neurocrine Biosciences by 6.6% during the first quarter. BlackRock Inc. now owns 13,466,650 shares of the company’s stock worth $1,363,094,000 after purchasing an additional 838,997 shares in the last quarter. State Street Corp increased its holdings in Neurocrine Biosciences by 4.1% during the second quarter. State Street Corp now owns 3,956,499 shares of the company’s stock worth $373,098,000 after buying an additional 156,584 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Neurocrine Biosciences by 20.7% in the first quarter. Renaissance Technologies LLC now owns 1,947,064 shares of the company’s stock valued at $197,082,000 after buying an additional 333,400 shares during the last quarter. Armistice Capital LLC boosted its position in Neurocrine Biosciences by 76.9% during the first quarter. Armistice Capital LLC now owns 1,592,000 shares of the company’s stock worth $161,142,000 after purchasing an additional 692,000 shares during the period. Finally, Geode Capital Management LLC grew its stake in Neurocrine Biosciences by 6.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,523,408 shares of the company’s stock valued at $143,431,000 after buying an additional 87,671 shares during the last quarter. 93.54% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Julie Cooke sold 824 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $110.93, for a total value of $91,406.32. Following the transaction, the insider now directly owns 17,263 shares in the company, valued at $1,914,984.59. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, insider Julie Cooke sold 824 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $110.93, for a total transaction of $91,406.32. Following the transaction, the insider now owns 17,263 shares in the company, valued at approximately $1,914,984.59. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jude Onyia sold 3,198 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $107.37, for a total transaction of $343,369.26. Following the sale, the insider now directly owns 9,638 shares in the company, valued at $1,034,832.06. The disclosure for this sale can be found here. Insiders sold 24,646 shares of company stock worth $2,663,790 in the last 90 days. 4.40% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.